Non-Small Cell Lung Cancer Market is expected to reach USD 76334.72 million by 2030

Non-Small Cell Lung Cancer Market Report gives an overview of a number of segments which are expected to grow the fastest during the estimated forecast period. This report helps to determine how the market will perform in the future years by providing details about the definition of the market, its classifications, its applications and its engagements. This report will be tailored to the needs of your business and deliver an exclusive, realistic and admirable analysis. Non-Small Cell Lung Cancer Market document is a tool that helps develop a marketing strategy and backbone for a business.

According to data published by the Institute for Clinical and Economic Review (ICER) and the National Institutes of Health (NIH), approximately 85% of lung cancer cases in the United States are NSCLC. Squamous cell carcinoma accounted for 30% of the cases, adenocarcinoma accounted for 40%, and large-cell carcinoma accounted for 15%. Furthermore, all other country-based registries reported nearly the same percentage of NSCLC and its major subtypes.

Data Bridge Market Research analyses that the non-small cell lung cancer market which is USD 26948.36 million in 2022, is expected to reach USD 76334.72 million by 2030, at a CAGR of 13.9% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Download the PDF Sample Report: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-non-small-cell-lung-cancer-market&Shri

Market Definition

Non-small cell lung carcinoma (NSCLC), also known as non-small cell lung cancer, is the most common type of lung cancer. The term “non-small cell” refers to the appearance of cancer cells under a microscope. Small cell lung cancer is named after the size of the cells (SCLC). According to the American Cancer Society, about 80 to 85 percentTrusted Source of all lung carcinomas fall into the non-small cell category. NSCLC is less likely to spread than SCLC and has a higher survival rate. The majority of people with early-stage NSCLC survive at least 5 years, but the survival rate is much lower if the cancer has spread to other tissues at the time of diagnosis.

Drivers

• Increase in Cancer Cases

The global increase in cancer cases boosts the global non-small cell lung cancer market during the forecast period. According to American Cancer Society statistics from 2016, the majority of cases of SCLC occur in people between the ages of 60 and 80, with a global death rate of 30,000 per year. Furthermore, according to WHO data, lung cancer is the second most common cancer in men and women, accounting for 1.59 million deaths in 2012. This boosts market growth.

• Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

• Development of Diversified Treatments

Patients are given treatments such as chemotherapy and radiation therapy to treat early-stage small cell lung cancer. These provide significant advantages to patients. Radiation therapy, for example, is given to patients to shrink tumour cells as well as relieve symptoms such as coughing, difficulty swallowing, bleeding, and shortness of breath. Three-dimensional conformal radiation therapy (3D-CRT) and intensity modulated radiation therapy (IMRT) are two types of radiation techniques commonly used in treatment.

• Rising Healthcare Awareness

The incidence of small cell lung cancer (SCLC) is becoming more widely known among patients and healthcare providers. Patients and doctors are now taking a more active role in learning about the therapies available for the treatment of these severe diseases. This is one of the most important market drivers. This expands the market’s opportunities.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained professionals who are unaware of treatment methods for this disease may limit the growth of the global non-small cell lung cancer market during the forecast period.

This non-small cell lung cancer market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the non-small cell lung cancer market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

View the Comprehensive Report: https://www.databridgemarketresearch.com/reports/global-non-small-cell-lung-cancer-market?Shri

Some of the major players operating in the non-small cell lung cancer market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Lilly (U.S.)
• Merck & Co., Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• CLOVIS ONCOLOGY (U.S.)
• Johnson & Johnson Private Limited (U.S.)

Recent Developments

• In 2019, Pfizer Inc., a multinational pharmaceutical and biotechnology corporation based in the United States, received European Commission (EC) marketing authorization for the LORVIQUA drug, a monotherapy drug used to treat anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
• In 2021, Daiichi Sankyo received FDA approval for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma.

Non-Small Cell Lung Cancer Market Scope

The non-small cell lung cancer market is segmented on the basis of cancer type, molecule type, drug class, treatment type, therapy type, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Cancer Type

• Non-Small Cell Lung Cancer
• Metastatic Lung Cancer
• Pulmonary Neuroendocrine Tumours
• Mediastina Tumours
• Mesothelioma
• Chest Wall Tumours

 Type

• Adenocarcinomas
• Squamous Cell Carcinoma
• Large Cell Carcinomas
• Others

Molecule Type

• Small Molecules
• Biologics

Drug Class

• Alkylating Agents
• Antimetabolites
• EGFR Inhibitors
• Mitotic Inhibitors
• Multi-kinase Inhibitors
• Others

 Treatment Type

• Chemotherapy
• Radiation Therapy
• Targeted Therapy
• Immunotherapy
• Others

Diagnosis

• CT Scan
• X-Rays
• Sputum Cytology
• Bronchoscopy
• Laboratory Tests
• Thoracoscopy
• Others

 Therapy Type

• Single Drug Therapy
• Combination Therapy

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

 Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online
• Others

Key Advantages of the Report: 

• This study provides an analytical overview of the industry, including current trends and future predictions to identify potential investment opportunities.
• The report offers insights into key drivers, limitations, and prospects, along with a comprehensive market share analysis.
• The report quantitatively assesses the current market, shedding light on its growth prospects.
• A Porter’s five forces analysis gauges the bargaining power of buyers and suppliers in the market.
• The report delivers an in-depth market analysis that considers competitive dynamics and forecasts the future competitive landscape.

 For the detailed report, which encompasses the full table of contents, tables, figures, graphs, and charts, please follow this link:  https://www.databridgemarketresearch.com/toc/?dbmr=global-non-small-cell-lung-cancer-market&Shri

What to Anticipate from the Report – A 7-Point Guide:

• The report delves into the holistic strategy and innovation within the market ecosystem.
• It highlights prominent market drivers and obstacles, providing clarity on technological standardization and regulatory frameworks.
• The report evaluates various implementation models and examines numerous use cases.
• Serving as a valuable resource, the report offers essential industry insights, showcasing information on new investments, stakeholders, relevant contributors, and market participants.
• Through the forecast period, the report conducts a thorough market analysis, referencing historical developments, ongoing events, and future growth prospects.

Top DBMR Healthcare Reports:         

Aesthetic/Cosmetic Lasers Market – Industry Trends and Forecast

Pharmaceutical Laboratory Information Management Systems Market – Industry Trends and Forecast

Automated Sample Storage Systems Market – Industry Trends and Forecast

Glaucoma Market – Industry Trends and Forecast

Clinical Trials Market – Industry Trends and Forecast

Esthetic Dental Restoration Products Market – Industry Trends and Forecast

Fractional Laser Market – Industry Trends and Forecast

Microbubble Contrast Media Market – Industry Trends and Forecast

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475

Email:- corporatesales@databridgemarketresearch.com